How to estimate ADMET properties of a new drug

Estimating ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity) is critical in drug discovery and development to predict the behavior of a drug in vivo. Here’s a detailed approach to estimating these properties:

---

1. Absorption

Absorption evaluates how effectively a drug enters systemic circulation after administration.

Key Factors:

• Solubility: Affects dissolution rate and bioavailability.
• Permeability: Indicates how well a drug crosses biological membranes.
• pKa: Determines ionization state, which influences absorption in different pH environments.

Methods of Estimation:

1. Experimental Techniques:

   • Caco-2 Cell Assay: Simulates intestinal epithelial permeability.
   • Parallel Artificial Membrane Permeability Assay (PAMPA): Assesses passive permeability.
   • Solubility Tests: Conducted in various pH buffers mimicking gastrointestinal conditions.

2. In Silico Models:

   • Lipinski’s Rule of Five: Predicts oral bioavailability using molecular weight, hydrogen bond donors/acceptors, and lipophilicity (logP).
   • QSAR Models (Quantitative Structure-Activity Relationships): Relate molecular features to absorption data.
   • GastroPlus®: Simulates gastrointestinal absorption.

---

2. Distribution

Distribution assesses how a drug disperses throughout the body’s tissues and fluids.

Key Factors:

• Volume of Distribution (Vd): Indicates the extent of drug distribution.
• Plasma Protein Binding (PPB): Impacts free drug availability.
• Tissue Binding: Influences drug accumulation in specific organs.

Methods of Estimation:

1. Experimental Techniques:

   • Equilibrium Dialysis or Ultrafiltration: Measures plasma protein binding.
   • Animal Studies: Assess tissue-specific concentrations.

2. In Silico Models:

   • LogP and LogD Calculations: Predict lipophilicity, a key determinant of tissue affinity.
   • Predictive Algorithms (e.g., pkCSM, ADMET Predictor): Estimate Vd and PPB from chemical structure.

---

3. Metabolism

Metabolism evaluates how a drug is chemically modified by enzymes, primarily in the liver.

Key Factors:

• Phase I Metabolism: Involves oxidation, reduction, or hydrolysis (e.g., by cytochrome P450 enzymes).
• Phase II Metabolism: Involves conjugation reactions like glucuronidation or sulfation.
• Metabolic Stability: Reflects the drug’s half-life in metabolic systems.

Methods of Estimation:

1. Experimental Techniques:

   • Liver Microsomes or Hepatocytes: Assess enzyme-mediated metabolism.
   • Cytochrome P450 Inhibition/Induction Studies: Identify potential drug-drug interactions.
   • Metabolite Identification: Using LC-MS/MS or NMR spectroscopy.

2. In Silico Models:

   • SMARTCyp: Predicts likely metabolic sites.
   • MetaSite and StarDrop: Simulate enzyme-substrate interactions.
   • Physiologically-Based Pharmacokinetic (PBPK) Models: Estimate drug clearance and metabolic pathways.

---

4. Excretion

Excretion assesses how the drug and its metabolites are eliminated from the body.

Key Factors:

• Renal Excretion: Includes glomerular filtration, tubular secretion, and reabsorption.
• Biliary Excretion: Drug elimination via bile.
• Half-life (t½): Indicates the duration of drug action.

Methods of Estimation:

1. Experimental Techniques:

   • In Vitro Transporter Assays: Evaluate interaction with renal and hepatic transporters (e.g., OATs, OCTs, P-gp).
   • Animal Models: Measure urinary and fecal excretion.

2. In Silico Models:

   • Clearance Predictions: Based on molecular size, charge, and hydrophobicity.
   • Transporter Interaction Models: Predict transporter-mediated excretion pathways.

---

5. Toxicity

Toxicity predicts adverse effects that a drug may induce.

Key Factors:

• Acute Toxicity: Evaluates single-dose lethality.
• Chronic Toxicity: Assesses long-term exposure effects.
• Organ-Specific Toxicity: Focus on liver, kidneys, and heart.
• Genotoxicity: Risk of DNA damage.
• Off-Target Effects: Interactions with unintended biological targets.

Methods of Estimation:

1. Experimental Techniques:

   • Cytotoxicity Assays: Using cell lines to assess viability (e.g., MTT, LDH assays).
   • hERG Assays: Test potential for cardiac arrhythmias.
   • In Vivo Studies: Evaluate systemic toxicity in animal models.

2. In Silico Models:

   • DEREK Nexus and ADMET Predictor: Assess structural alerts for toxicity.
   • T.E.S.T. (Toxicity Estimation Software Tool): Predicts various toxicity endpoints.
   • QSAR for Specific Toxicity: Models for mutagenicity, carcinogenicity, or reproductive toxicity.

---

Integrated Approaches for ADMET Estimation

1. High-Throughput Screening (HTS):

   • Combines automated assays for multiple ADMET parameters.
   • Prioritizes compounds with favorable profiles.

2. In Silico Workflow:

   • Use cheminformatics platforms like Schrödinger’s QikProp or ADMETlab for rapid screening of ADMET properties.

3. PBPK Modeling:

   • Combines ADMET data with physiological parameters for holistic predictions of drug behavior in humans.

4. Machine Learning Models:

   • Utilize datasets of known drugs to predict ADMET properties based on chemical descriptors.

---

Conclusion

By integrating experimental data with in silico predictions, researchers can efficiently estimate ADMET properties and prioritize promising drug candidates for further development. Balancing cost, speed, and accuracy is key to successful ADMET profiling.